TrialCurveATTRACTION-2 (prior trastuzumab subgroup): reconstructed Kaplan–Meier curves
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Gastric Cancer. 2019 May 13;23(1):143–53. doi: 10.1007/s10120-019-00970-8 |
|---|---|
| DOI | 10.1007/s10120-019-00970-8 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — Tmab+ patients
From figure panel a · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Nivolumab 8.2 months; Placebo 3.0 months. Survival at 12 months: Nivolumab 39%; Placebo 9%. Hazard ratio Nivolumab vs Placebo 0.40 (95% CI 0.24–0.69).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 59 | 42 | 8.2 |
| Placebo | 22 | 21 | 3.0 |
- Nivolumab vs Placebo: reconstructed HR 0.40 (95% CI 0.24–0.69)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 6 mo | 55.4% | 27.3% |
| 12 mo | 39.4% | 9.1% |
| 18 mo | 28.2% | 4.5% |
| 24 mo | 19.8% | — |
Checks against the published figure
- Nivolumab median: printed 8.3, reconstructed 8.24 pass
- Placebo median: printed 3.1, reconstructed 2.97 pass
- hazard ratio: printed 0.38, reconstructed 0.404 pass
Overall survival — Tmab− patients
From figure panel b · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Nivolumab 4.9 months; Placebo 4.2 months. Survival at 12 months: Nivolumab 25%; Placebo 12%. Hazard ratio Nivolumab vs Placebo 0.72 (95% CI 0.57–0.89).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 271 | 217 | 4.9 |
| Placebo | 141 | 128 | 4.2 |
- Nivolumab vs Placebo: reconstructed HR 0.72 (95% CI 0.57–0.89)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 6 mo | 43.6% | 36.0% |
| 12 mo | 24.6% | 12.0% |
| 18 mo | 13.8% | 4.5% |
| 24 mo | 9.6% | 4.5% |
Checks against the published figure
- Nivolumab median: printed 4.8, reconstructed 4.94 pass
- Placebo median: printed 4.2, reconstructed 4.19 pass
- hazard ratio: printed 0.71, reconstructed 0.715 pass
Progression-free survival — Tmab+ patients
From figure panel c · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Nivolumab 1.6 months; Placebo 1.5 months. Survival at 6 months: Nivolumab 33%. Hazard ratio Nivolumab vs Placebo 0.47 (95% CI 0.28–0.80).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 59 | 50 | 1.6 |
| Placebo | 22 | 22 | 1.5 |
- Nivolumab vs Placebo: reconstructed HR 0.47 (95% CI 0.28–0.80)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 3 mo | 38.0% | 18.2% |
| 6 mo | 32.6% | — |
| 9 mo | 21.3% | — |
| 12 mo | 17.1% | — |
| 15 mo | 6.2% | — |
Checks against the published figure
- Nivolumab median: printed 1.6, reconstructed 1.55 pass
- Placebo median: printed 1.48, reconstructed 1.47 pass
- hazard ratio: printed 0.49, reconstructed 0.469 pass
Progression-free survival — Tmab− patients
From figure panel d · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Nivolumab 1.6 months; Placebo 1.5 months. Survival at 12 months: Nivolumab 8%; Placebo 2%. Hazard ratio Nivolumab vs Placebo 0.63 (95% CI 0.51–0.79).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 271 | 221 | 1.6 |
| Placebo | 141 | 126 | 1.5 |
- Nivolumab vs Placebo: reconstructed HR 0.63 (95% CI 0.51–0.79)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 6 mo | 18.9% | 8.2% |
| 12 mo | 7.8% | 1.8% |
| 18 mo | 4.9% | 0.9% |
| 24 mo | 2.4% | — |
Checks against the published figure
- Nivolumab median: printed 1.6, reconstructed 1.59 pass
- Placebo median: printed 1.5, reconstructed 1.49 pass
- hazard ratio: printed 0.64, reconstructed 0.635 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/attraction-2-prior-trastuzumab-subgroup-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/attraction-2-prior-trastuzumab-subgroup-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Gastric Cancer. 2019 May 13;23(1):143–53. doi: 10.1007/s10120-019-00970-8 doi:10.1007/s10120-019-00970-8. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/attraction-2-prior-trastuzumab-subgroup
Report a problem with these data
Related trials
- ATTRACTION-2 (2-year update): Overall survival; Progression-free survival
- JACOB (Chinese subgroup): Overall survival; Progression-free survival (investigator-assessed)
- Gastrectomy and second-line chemotherapy in advanced gastric cancer: Overall survival; Overall survival (IPTW-adjusted); Progression-free survival; Progression
- ATTRACTION-2 (Japanese subgroup): Overall survival; Progression-free survival
- Preoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: Disease-free survival; Overall survival
- GLOW: Overall survival; Progression-free survival; Progression-free survival (investigator-asses
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials